NGNE Neurogene Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1404644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-40.0%
TTM EPS YoY-22.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-38.4%
ROA-35.8%
ROIC (approx.)-43.7%
Asset turnover—
Leverage & solvency
Liabilities / assets6.1%
Debt / equity0.00x
Current ratio19.97x
Interest coverage-129,924.00x
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | — | $0 |
| R&D expense | $23.52M | $25.47M | $25.15M | $20.64M | $17.24M | $19.37M | $17.76M | $15.35M |
| SG&A expense | $8.85M | $11.20M | $8.20M | $6.89M | $6.56M | $6.71M | $8.16M | $6.17M |
| Operating income | -$32.38M | -$36.67M | -$33.35M | -$27.53M | -$23.80M | -$26.08M | -$25.92M | -$21.51M |
| Interest expense | $0 | $0 | $0 | $1,000 | $1,000 | $1,000 | $2,000 | $2,000 |
| Net income | -$29.02M | -$34.49M | -$30.93M | -$24.73M | -$20.95M | -$22.02M | -$22.65M | -$19.51M |
| EBITDA | -$31.55M | -$35.86M | -$32.50M | -$26.75M | -$23.00M | -$25.28M | -$25.17M | -$20.73M |
| EPS (basic) | -1.05 | -1.53 | -1.39 | — | -0.99 | -1.05 | -1.08 | — |
| EPS (diluted) | -1.05 | -1.53 | -1.39 | — | -0.99 | -1.05 | -1.08 | — |
| Weighted avg. shares (diluted) | 27.70M | 22.55M | 22.31M | — | 21.17M | 21.06M | 21.00M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $78.94M | $112.48M | $124.16M | $103.84M | $71.34M | $59.15M | $71.11M | $136.93M |
| Short-term investments | $280.78M | $112.91M | $119.02M | $165.17M | $194.41M | $215.71M | $221.83M | $175.82M |
| Current assets | $362.74M | $228.91M | $246.75M | $271.77M | $270.52M | $278.99M | $296.40M | $315.92M |
| PP&E, net | $11.19M | $11.73M | $12.50M | $12.79M | $13.48M | $14.25M | $14.81M | $15.42M |
| Total assets | $377.90M | $244.36M | $263.14M | $288.60M | $287.83M | $297.32M | $315.30M | $335.73M |
| Current liabilities | $18.16M | $21.50M | $18.87M | $16.41M | $14.71M | $15.44M | $14.09M | $15.16M |
| Total liabilities | $23.11M | $27.23M | $25.36M | $23.72M | $22.29M | $24.06M | $23.51M | $25.36M |
| Shareholders' equity | $354.79M | $217.13M | $237.78M | $264.89M | $265.54M | $273.25M | $291.80M | $310.38M |
| Shares outstanding | 20.69M | 15.83M | 15.62M | 15.49M | 14.78M | 14.27M | 14.93M | 14.85M |
| Cash flow statement | ||||||||
| Operating cash flow | -$29.14M | -$23.76M | -$26.12M | -$17.43M | -$19.51M | -$19.46M | -$20.77M | -$17.50M |
| Capital expenditure | $315,000 | $354,000 | $281,000 | $128,000 | $127,000 | $148,000 | $780,000 | $116,000 |
| Free cash flow | -$29.46M | -$24.11M | -$26.40M | -$17.56M | -$19.64M | -$19.61M | -$21.55M | -$17.61M |
| Investing cash flow | -$165.99M | $6.10M | $46.24M | $29.61M | $21.99M | $7.45M | -$45.05M | -$102.62M |
| Financing cash flow | $161.60M | $5.98M | $195,000 | $20.66M | $9.71M | $54,000 | $4,000 | $190.06M |
| Depreciation & amortization | $821,000 | $813,000 | $847,000 | $776,000 | $800,000 | $800,000 | $749,000 | $785,000 |
| Stock-based compensation | $5.15M | $7.86M | $3.63M | $3.36M | $3.37M | $3.41M | $4.05M | $2.49M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.